Cat No.R-076
Product TypeGrowth factor
Molecular Weight16.5 kDa
SterilityNegative
MyCoplasmaNegative
Purity≥ 97 % as determined by SDS-PAGE
Expression SystemHuman 293 cells (HEK293)
FormulationLyophilized from sterile PBS, pH7.4, with 5% - 8% trehalose, mannitol, and 0.01% Tween80 as protectants.
ReconstitutionPlease refer to the Certificate of Analysis (CoA) for specific reconstitution instructions.
Shipping InfoIce
Stability & StorageStore frozen at -20 °C (short-term) or -80°C (long-term)

View Product Image

Description

Recombinant Human basic FGF/FGF2 Protein, Tag-Free is a member of the fibroblast growth factor family involved in bone healing, cartilage repair, bone regeneration, and nerve regeneration. FGF-2 also acts as a mitotic promoter, accelerating cell proliferation. It regulates immune processes by specifically targeting tyrosine kinase receptors and activating the FGF/FGFR signaling pathway. For instance, FGF-2 participates in the JAK-STAT signaling pathway to regulate cartilage metabolism and activates the ERK signaling pathway to promote cartilage regeneration. Additionally, FGF-2 in combination with FGFR1/3 promotes both the degeneration and repair of articular cartilage. FGF-2 is also a known carcinogen in GBM (glioblastoma multiforme), contributing to glioma growth and vascularization.

Specifications & Applications

Application

For research use only.

Tags

Inquiring Recombinant Human Basic FGF/FGF2 Protein, Tag-Free

We know how valuable your research is to you, but are you wondering what you can expect to pay for quick accurate results every time? Fill out a request in the form below and we’ll get back to you within 24 hours with a quote.

Whether you're exploring disease mechanisms or screening novel therapeutics, OgCelix is your trusted partner.

Let's build the future of translational research together.

Let's Talk Now

Whether you're exploring disease mechanisms or screening novel therapeutics, OgCelix is your trusted partner.

Let's build the future of translational research together.

Let's Talk Now